Matches in SemOpenAlex for { <https://semopenalex.org/work/W4246332979> ?p ?o ?g. }
Showing items 1 to 93 of
93
with 100 items per page.
- W4246332979 endingPage "TPS5598" @default.
- W4246332979 startingPage "TPS5598" @default.
- W4246332979 abstract "TPS5598 Background: TALA blocks poly(ADP-ribose) polymerase (PARP) activity and traps PARP on single-strand DNA breaks, preventing DNA damage repair (DDR) and causing death of cells with DDR alterations (eg BRCA1/2). a TALA has been approved in multiple countries as monotherapy for germline BRCA1/2-mutated human epidermal growth factor receptor 2-negative advanced breast cancer. ENZA is an androgen receptor (AR) inhibitor and an established therapy for mCRPC. As PARP activity has been shown to support AR function, inhibition of PARP is expected to reduce AR signaling and increase sensitivity to AR-directed therapies. In addition, AR blockade downregulates homologous recombination repair gene transcription which induces ‘ BRCAness ’. Therefore, combining TALA with ENZA in mCRPC may be efficacious regardless of DDR alterations. TALAPRO-2 (NCT03395197) is a Phase III, 2-part study to evaluate efficacy, safety, pharmacokinetics, and patient-reported outcomes (PROs) of TALA combined with ENZA. Methods: Enrollment goal is 1037 patients (19 patients, part 1 dose-finding; 1,018 patients, part 2 placebo-controlled). Key eligibility criteria: age ≥18 years; asymptomatic/mildly symptomatic mCRPC; ECOG performance status ≤1; metastatic disease (no brain metastases); and no prior life-prolonging systemic therapy for nonmetastatic CRPC or mCRPC. Prior therapies (excluding novel AR inhibitors) in the castration-sensitive (CSPC) setting are allowed. ADT must continue throughout the study. The randomized double-blind portion (part 2) will evaluate safety, efficacy, and PROs of TALA (0.5 mg QD) + ENZA (160 mg QD) vs placebo + ENZA (160 mg QD). Patients are stratified by prior novel hormonal therapy or docetaxel for CSPC (yes or no) and DDR alteration status (deficient vs nondeficient/unknown). The primary endpoint is radiographic progression-free survival (rPFS), defined as time to progression in soft tissue per RECIST v.1.1 or in bone per PCWG3 criteria by independent review or death. The key secondary endpoint is overall survival. Efficacy will be assessed radiographically every 8 weeks up to Week 25 and every 8–12 weeks thereafter. rPFS will be compared between the two arms by a 1-sided stratified log-rank test. Patient recruitment is ongoing in multiple regions including US, Europe/Eastern Europe, Israel, South America, South Africa, and Asia-Pacific region. a DDR alterations are defined as known/likely pathogenic variants or homozygous deletions. Funding: Pfizer Inc. Clinical trial information: NCT03395197 ." @default.
- W4246332979 created "2022-05-12" @default.
- W4246332979 creator A5003589050 @default.
- W4246332979 creator A5007779528 @default.
- W4246332979 creator A5010946186 @default.
- W4246332979 creator A5018831568 @default.
- W4246332979 creator A5024685539 @default.
- W4246332979 creator A5050035884 @default.
- W4246332979 creator A5060911926 @default.
- W4246332979 creator A5075093609 @default.
- W4246332979 creator A5075458297 @default.
- W4246332979 creator A5077071889 @default.
- W4246332979 creator A5080507578 @default.
- W4246332979 creator A5085689787 @default.
- W4246332979 creator A5087989455 @default.
- W4246332979 creator A5088518998 @default.
- W4246332979 date "2020-05-20" @default.
- W4246332979 modified "2023-10-17" @default.
- W4246332979 title "TALAPRO-2: a placebo-controlled phase III study of talazoparib (TALA) plus enzalutamide (ENZA) for patients with first-line metastatic castration-resistant prostate cancer (mCRPC)." @default.
- W4246332979 doi "https://doi.org/10.1200/jco.2020.38.15_suppl.tps5598" @default.
- W4246332979 hasPublicationYear "2020" @default.
- W4246332979 type Work @default.
- W4246332979 citedByCount "2" @default.
- W4246332979 countsByYear W42463329792021 @default.
- W4246332979 countsByYear W42463329792022 @default.
- W4246332979 crossrefType "journal-article" @default.
- W4246332979 hasAuthorship W4246332979A5003589050 @default.
- W4246332979 hasAuthorship W4246332979A5007779528 @default.
- W4246332979 hasAuthorship W4246332979A5010946186 @default.
- W4246332979 hasAuthorship W4246332979A5018831568 @default.
- W4246332979 hasAuthorship W4246332979A5024685539 @default.
- W4246332979 hasAuthorship W4246332979A5050035884 @default.
- W4246332979 hasAuthorship W4246332979A5060911926 @default.
- W4246332979 hasAuthorship W4246332979A5075093609 @default.
- W4246332979 hasAuthorship W4246332979A5075458297 @default.
- W4246332979 hasAuthorship W4246332979A5077071889 @default.
- W4246332979 hasAuthorship W4246332979A5080507578 @default.
- W4246332979 hasAuthorship W4246332979A5085689787 @default.
- W4246332979 hasAuthorship W4246332979A5087989455 @default.
- W4246332979 hasAuthorship W4246332979A5088518998 @default.
- W4246332979 hasConcept C121608353 @default.
- W4246332979 hasConcept C126322002 @default.
- W4246332979 hasConcept C142724271 @default.
- W4246332979 hasConcept C143998085 @default.
- W4246332979 hasConcept C182979987 @default.
- W4246332979 hasConcept C204787440 @default.
- W4246332979 hasConcept C27081682 @default.
- W4246332979 hasConcept C2776551883 @default.
- W4246332979 hasConcept C2779138821 @default.
- W4246332979 hasConcept C2780192828 @default.
- W4246332979 hasConcept C54355233 @default.
- W4246332979 hasConcept C552990157 @default.
- W4246332979 hasConcept C61367390 @default.
- W4246332979 hasConcept C71924100 @default.
- W4246332979 hasConcept C82381507 @default.
- W4246332979 hasConcept C86803240 @default.
- W4246332979 hasConceptScore W4246332979C121608353 @default.
- W4246332979 hasConceptScore W4246332979C126322002 @default.
- W4246332979 hasConceptScore W4246332979C142724271 @default.
- W4246332979 hasConceptScore W4246332979C143998085 @default.
- W4246332979 hasConceptScore W4246332979C182979987 @default.
- W4246332979 hasConceptScore W4246332979C204787440 @default.
- W4246332979 hasConceptScore W4246332979C27081682 @default.
- W4246332979 hasConceptScore W4246332979C2776551883 @default.
- W4246332979 hasConceptScore W4246332979C2779138821 @default.
- W4246332979 hasConceptScore W4246332979C2780192828 @default.
- W4246332979 hasConceptScore W4246332979C54355233 @default.
- W4246332979 hasConceptScore W4246332979C552990157 @default.
- W4246332979 hasConceptScore W4246332979C61367390 @default.
- W4246332979 hasConceptScore W4246332979C71924100 @default.
- W4246332979 hasConceptScore W4246332979C82381507 @default.
- W4246332979 hasConceptScore W4246332979C86803240 @default.
- W4246332979 hasFunder F4320307765 @default.
- W4246332979 hasIssue "15_suppl" @default.
- W4246332979 hasLocation W42463329791 @default.
- W4246332979 hasOpenAccess W4246332979 @default.
- W4246332979 hasPrimaryLocation W42463329791 @default.
- W4246332979 hasRelatedWork W2590294003 @default.
- W4246332979 hasRelatedWork W2770702948 @default.
- W4246332979 hasRelatedWork W2783882412 @default.
- W4246332979 hasRelatedWork W2977620704 @default.
- W4246332979 hasRelatedWork W3014214351 @default.
- W4246332979 hasRelatedWork W3023947295 @default.
- W4246332979 hasRelatedWork W3136835288 @default.
- W4246332979 hasRelatedWork W4205706045 @default.
- W4246332979 hasRelatedWork W4229076799 @default.
- W4246332979 hasRelatedWork W4295836975 @default.
- W4246332979 hasVolume "38" @default.
- W4246332979 isParatext "false" @default.
- W4246332979 isRetracted "false" @default.
- W4246332979 workType "article" @default.